Monthly Archives: March 2022

Not discussed in detail but logical follow up – can we learn about the pathophysiology o psychosis from his neuropathic correlation as I suggested in 1986 poster to APA. Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology | Dementia and Cognitive Impairment | JAMA Network OpenContinue reading “Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology”

WASHINGTON, D.C., March 2, 2022 – Today, the American Psychiatric Association CEO and Medical Director Saul Levin, M.D., M.P.A., and Chair of APA Committee on the Psychiatric Dimensions of Disaster Joshua Morganstein, M.D., offered the following APA statement and resources in response to the War in Ukraine: .. The APA supports the care of allContinue reading “APA Statement on the War in Ukraine”

FDA-Approved Weight Loss Drugs: Can They Help You? Joseph (Joe) E. Thornton, M.D., DFAPA Adjunct Clinical Associate Professor, Psychiatry University of Florida College of Medicine joethornton@ufl.edu CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privilegedContinue reading “Drugs.com overview of weight loss medications”

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwi8tqvF1Kr2AhWqQTABHUiuBOYQFnoECAYQAQ&url=https%3A%2F%2Fwww.niddk.nih.gov%2Fhealth-information%2Fweight-management%2Fprescription-medications-treat-overweight-obesity&usg=AOvVaw0it2lzmOGFSzxpaGNWpADh Joseph (Joe) E. Thornton, M.D., DFAPA

Semaglutide JAMA 2022 Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial | Lifestyle Behaviors | JAMA | JAMA Network Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body WeightContinue reading “Semaglutide JAMA 2022”

Semaglutide Medscape article in 2020 Major Breakthrough in Weight Loss With Semaglutide? (medscape.com) In a phase 3 trial where all participants received intensive behavior therapy, investigational 2.4-mg once-weekly subcutaneous semaglutide (Novo Nordisk) resulted in a 10.3% greater average weight loss than placebo over a period of 68 weeks. If approved, this medication could be aContinue reading “Semaglutide Medscape article in 2020”

Joseph (Joe) E. Thornton, M.D., DFAPA Adjunct Clinical Associate Professor, Psychiatry University of Florida College of Medicine joethornton@ufl.edu CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are privateContinue reading “Additional Medicaid CBTi/Sleep Service Updates”

Sublingual Dexmedetomidine as a Potential New Treatment for Agitation John K. Hsiao, MD1 Author Affiliations Article Information JAMA. 2022;327(8):723-725. doi:10.1001/jama.2021.21313 An out-of-control, agitated, possibly aggressive patient in a medical setting is a crisis demanding swift and safe resolution. Traditionally, behavioral agitation, often due to psychosis, was managed by psychiatry, particularly when physical restraints were theContinue reading “Sublingual Dexmedetomidine as a Potential New Treatment for Agitation”

The Lancet ⁦‪@TheLancet‬⁩ This study suggests choice of antipsychotic for maintenance treatment of adults with schizophrenia should be guided mainly by tolerability; authors report no clear differences between antipsychotics for relapse prevention. hubs.li/Q0156dN20 pic.twitter.com/2MGZz34Ven 3/1/22, 12:04 PM Joseph (Joe) E. Thornton, M.D., DFAPA